Jing Liu

Jing Liu

  • Subject： Regenerative Medicine
  • Tel/Fax: +86-10-64806297  / 
  • Email： liujing@ioz.ac.cn
  • Address： The State Key Laboratory of Stem cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, 1BeichenWest Road, Chaoyang District, Beijing 100101, P.R.China
  • More： Stem Cell and Neural Regeneration Research Group      

Resume

Jing Liu, Ph.D., Associate Professor, is a member of the Stem Cell and Neural Regeneration Research Group at the Institute of Zoology, Chinese Academy of Sciences. He received his Ph.D. in Medicine from the Institute of Zoology, Chinese Academy of Sciences in 2021, under the supervision of Prof. Baoyang Hu. He subsequently conducted postdoctoral research at the same institute and was promoted to Associate Professor in 2026.

Dr. Liu has long been engaged in developing biotherapeutic strategies for Alzheimer’s disease. His research focuses on the clearance of amyloid-β (Aβ) pathological proteins, with systematic investigations spanning multiple approaches, including small-molecule interventions, cell therapy, gene therapy, and targeted protein degradation.

He has published multiple research articles as first or co-first author in leading international journals such as Cell and Immunity. As a key contributor, he has participated in several major research programs, including the National Key R&D Program of China project titled “Immune Microenvironment in Neurodegenerative Diseases and Its Interaction with Neural Stem Cells,” as well as the Chinese Academy of Sciences Strategic Priority Research Program “Development of Immune-Coupled Organoids and Evaluation of Immunotherapeutics.”

Research Grants

Strategic Priority Research Program (Category B), Chinese Academy of Sciences

Project No. XDB1480201; Oct 2025 – Sep 2030; Ongoing; Participant

Strategic Priority Research Program (Category A), Chinese Academy of Sciences

Project No. XDA046205; Jul 2024 – Jun 2029; Ongoing; Participant

National Key R&D Program of China, Ministry of Science and Technology

Project No. 2021YFA1101402; Dec 2021 – Jun 2026; Ongoing; Participant

Selected Publications

1 Hou Z#, Liu K#, Li C#, Wu J*, Liu J*, Hu B*. Infusion of immunity- and matrix-regulatory cells as a protective strategy against premature death triggered by severe sleep deprivation. Chin Med J (Engl). Published online March 13, 2026.

2 Teng, F#., Liu, J#., Cui, T#., Tan, X#., Liu, K#., Hou, Z#., Zhou, L., Xie, Y., Li, R., Li, D., Li, B., Wang, D., Zhou*, Q., Hu, B*., & Li, W*. (2026). Efficient amyloid-β degradation in Alzheimer's disease using SPYTACs. Cell, 189(7), 1923–1941.e26.

3 Liu, K., Chen, X., Fan, Z., Ren, F*., Liu, J*., & Hu, B*. (2025). From organoids to organoids-on-a-chip: Current applications and challenges in biomedical research. Chinese medical journal, 138(7), 792–807.

4 Xie, Y#., Liu, J#., Hou, Z#., Wang, H#., Liu, K., Chen, X., Fan, Z., Li, D., Li, C., Pan, Y., Zhao, Y., Zhu, Y*., & Hu, B*. (2025). CD4-Derived Double-Negative T Cells Ameliorate Alzheimer's Disease-Like Phenotypes in the 5×FAD Mouse Model. CNS neuroscience & therapeutics, 31(1), e70187.

5 Liu, J#., Wang, Z#., Liang, W., Zhang, Z., Deng, Y., Chen, X., Hou, Z., Xie, Y., Wang, Q., Li, Y., Bai, C., Li, D., Mo, F., Wang, H., Wang, D., Yuan, J*., Wang, Y*., Teng, Z. Q*., & Hu, B*. (2025). Microglial TMEM119 binds to amyloid-β to promote its clearance in an Aβ-depositing mouse model of Alzheimer's disease. Immunity, 58(7), 1830–1846.e7.

6 Liu, J#., Hou, Z#., Wu, J#., Liu, K., Li, D., Gao, T., Liu, W., An, B., Sun, Y., Mo, F., Wang, L., Wang, Y*., Hao, J*., & Hu, B*. (2021). Infusion of hESC derived Immunity-and-matrix regulatory cells improves cognitive ability in early-stage AD mice. Cell proliferation, 54(8), e13085.

7 Sun, H., Liu, J., Li, S., Zhou, L., Wang, J., Liu, L., Lv, F., Gu, Q., Hu, B., Ma, Y., & Wang, S. (2019). Reactive Amphiphilic Conjugated Polymers for Inhibiting Amyloid β Assembly. Angewandte Chemie (International ed. in English), 58(18), 5988–5993.